JP5694782B2 - 肺癌、腺癌及び他の病状のための治療方法及び組成物 - Google Patents

肺癌、腺癌及び他の病状のための治療方法及び組成物 Download PDF

Info

Publication number
JP5694782B2
JP5694782B2 JP2010550647A JP2010550647A JP5694782B2 JP 5694782 B2 JP5694782 B2 JP 5694782B2 JP 2010550647 A JP2010550647 A JP 2010550647A JP 2010550647 A JP2010550647 A JP 2010550647A JP 5694782 B2 JP5694782 B2 JP 5694782B2
Authority
JP
Japan
Prior art keywords
paclitaxel
cisplatin
dithio
bis
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010550647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514355A5 (cg-RX-API-DMAC7.html
JP2011514355A (ja
Inventor
ハウシェール，フレデリック，エイチ．
Original Assignee
バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド filed Critical バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド
Publication of JP2011514355A publication Critical patent/JP2011514355A/ja
Publication of JP2011514355A5 publication Critical patent/JP2011514355A5/ja
Application granted granted Critical
Publication of JP5694782B2 publication Critical patent/JP5694782B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
JP2010550647A 2008-03-14 2008-03-14 肺癌、腺癌及び他の病状のための治療方法及び組成物 Active JP5694782B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/003405 WO2009113983A1 (en) 2008-03-14 2008-03-14 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Publications (3)

Publication Number Publication Date
JP2011514355A JP2011514355A (ja) 2011-05-06
JP2011514355A5 JP2011514355A5 (cg-RX-API-DMAC7.html) 2011-06-16
JP5694782B2 true JP5694782B2 (ja) 2015-04-01

Family

ID=41065492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550647A Active JP5694782B2 (ja) 2008-03-14 2008-03-14 肺癌、腺癌及び他の病状のための治療方法及び組成物

Country Status (6)

Country Link
EP (1) EP2249825B1 (cg-RX-API-DMAC7.html)
JP (1) JP5694782B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008352597B2 (cg-RX-API-DMAC7.html)
CA (1) CA2717181C (cg-RX-API-DMAC7.html)
DK (1) DK2249825T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009113983A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471431B2 (en) * 2010-09-16 2022-10-18 Lantern Pharma Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
CN109619552A (zh) * 2018-12-05 2019-04-16 贾志丹 适用于肿瘤患者的营养治疗型配方及制备方法、用途
CN113906010A (zh) * 2019-03-08 2022-01-07 蓝腾制药公司 治疗患有非小细胞肺癌的女性非吸烟者的方法
CN115040549A (zh) * 2022-06-07 2022-09-13 广东特芯生物科技有限公司 一种用于肿瘤的组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US4657927A (en) 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
US4310515A (en) 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4915956A (en) 1987-12-16 1990-04-10 Lyphomed, Inc. Liquid cisplatin formulations
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
CN1138541C (zh) 1994-08-08 2004-02-18 德彪药品股份有限公司 一种药学上稳定的奥沙利铂制剂
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DE19617802A1 (de) 1996-05-03 1997-11-06 Basf Ag Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
AU712548B2 (en) * 1996-09-23 1999-11-11 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
US6160167A (en) 1998-04-21 2000-12-12 Bionumerik Pharmaceuticals, Inc. Mercaptans and disulfides
WO2002056755A2 (en) * 2001-01-19 2002-07-25 Bionumerik Pharmaceuticals, Inc. Method for treating cancer
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US6504049B1 (en) 2002-04-30 2003-01-07 Bionumerik Pharmaceuticals, Inc. Process for synthesizing pharmaceutically active disulfide salts
US20050256055A1 (en) 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
CA2647297A1 (en) * 2006-03-16 2007-09-27 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
JP6516187B2 (ja) 2015-07-23 2019-05-22 パナソニックＩｐマネジメント株式会社 眠気判定装置、眠気判定方法、眠気判定プログラムおよび記録媒体

Also Published As

Publication number Publication date
DK2249825T3 (en) 2016-01-11
AU2008352597B2 (en) 2012-03-08
AU2008352597A1 (en) 2009-09-17
EP2249825A4 (en) 2011-10-05
EP2249825A1 (en) 2010-11-17
EP2249825B1 (en) 2015-10-07
WO2009113983A1 (en) 2009-09-17
CA2717181A1 (en) 2009-09-17
CA2717181C (en) 2013-10-15
JP2011514355A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
JP6621501B2 (ja) 新規癌治療法としてのアリール炭化水素受容体（ＡｈＲ）改変物質
JP7564119B2 (ja) ナルトレキソン及びカンナビノイドを含む癌の治療
JP7193591B2 (ja) 化学療法の改善
US20120294957A1 (en) Treatment of lung cancer
JP5667886B2 (ja) 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
Wu et al. Quercetin induced NUPR1-dependent autophagic cell death by disturbing reactive oxygen species homeostasis in osteosarcoma cells
JPWO2015178426A1 (ja) がん幹細胞の増殖抑制剤
TW202028182A (zh) 用於癌症治療之免疫調節之組合
JP5694782B2 (ja) 肺癌、腺癌及び他の病状のための治療方法及び組成物
Harada et al. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines
US20090232906A1 (en) Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
AU2010224108A1 (en) Treatment of pancreatic cancer
US20230210794A1 (en) Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
TW202106292A (zh) 難治性癌症之預防或治療用之醫藥組合物
JP2019520310A (ja) 癌及び前癌病変に対する治療剤、治療方法、及び治療薬剤製造方法
CA3017557A1 (en) Combination therapy for proliferative diseases
RU2678103C2 (ru) Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта
CN105142643A (zh) 药物化合物
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
CN104606189B (zh) 一种化合物在制备mTOR抑制剂中的应用
JP2022528454A (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
AU2010336256A1 (en) Antitumor Agent or Postoperative Adjuvant Chemotherapeutic Agent for Hepatocellular Carcinoma Treatment
WO2024186961A1 (en) Mitochondria-targeted agents for disease prevention and treatment
WO2020229685A1 (en) Combination therapy for proliferative conditions
JPWO2015152409A1 (ja) タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150205

R150 Certificate of patent or registration of utility model

Ref document number: 5694782

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250